Gilead Sciences Inc. closed 8.32% below its 52-week high of $119.96, which the company reached on March 10th.

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...

Nick doubles down on being the villain when he’s back in New Bethlehem, and tells Rita that he no longer thinks he’s able to ...

Let’s just say you wake up one morning in The Handmaid’s Tale universe, stuck inside the color-coded hellscape that is Gilead ...

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: ...

The ultraconservative dictatorship in which the series based on Margaret Atwood’s novel is set is becoming less and less unthinkable ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.